Investors & Media

What’s new.

Press releases

Press releases.

May 15th 2024

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 2nd 2024

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

April 29th 2024

Immutep Quarterly Activities Report Q3 FY24

more

Investor updates

Investor updates.

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

November 17th 2022

Investor Update - November 2022

more

Analyst reports

Analyst reports.

May 16th 2024

CLSA - Higher dosing showing promise; MBC efti+chemo dose escalation complete response, no safety concerns; Rated BUY, A$0.95 (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 15th 2024

Canaccord Genuity - Efti poster at ESMO: Continued safety is a win; Rated Buy, A$1 Price Target ( Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 3rd 2024

Bell Potter - More Great Data, Major Catalyst Nears; Maintain Buy, A$0.80 Valuation (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

more